<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Cancer Biol Med</journal-id><journal-id journal-id-type="iso-abbrev">Cancer Biol Med</journal-id><journal-id journal-id-type="publisher-id">CBM</journal-id><journal-title-group><journal-title>Cancer Biology &#x00026; Medicine</journal-title></journal-title-group><issn pub-type="ppub">2095-3941</issn><publisher><publisher-name>Chinese Anti-Cancer Association</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25859406</article-id><article-id pub-id-type="pmc">4383848</article-id><article-id pub-id-type="publisher-id">cbm-12-01-001</article-id><article-id pub-id-type="doi">10.7497/j.issn.2095-3941.2015.0006</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title><italic>HOTAIR</italic>: an oncogenic long non-coding RNA in different cancers</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Hajjari</surname><given-names>Mohammadreza</given-names></name></contrib><contrib contrib-type="author"><name><surname>Salavaty</surname><given-names>Abbas</given-names></name></contrib><aff id="aff1">Department of Genetics, Faculty of Science, Shahid Chamran University of Ahvaz, Ahvaz 61336-3337, <country>Iran</country></aff></contrib-group><author-notes><fn id="afn1"><p>Correspondence to: Mohammadreza Hajjari</p></fn><fn id="afn2"><p>E-mail: <email xlink:href="Mohamad.hajari@gmail.com">Mohamad.hajari@gmail.com</email>, <email xlink:href="M-hajari@scu.ac.ir">M-hajari@scu.ac.ir</email></p></fn></author-notes><pub-date pub-type="epub-ppub"><month>3</month><year>2015</year></pub-date><!--Fake ppub date generated by PMC from publisher
							pub-date/@pub-type='epub-ppub' --><pub-date pub-type="ppub"><month>3</month><year>2015</year></pub-date><volume>12</volume><issue>1</issue><fpage>1</fpage><lpage>9</lpage><history><date date-type="received"><day>17</day><month>1</month><year>2015</year></date><date date-type="accepted"><day>12</day><month>2</month><year>2015</year></date></history><permissions><copyright-statement>2015 Cancer Biology &#x00026; Medicine</copyright-statement><copyright-year>2015</copyright-year><copyright-holder>Cancer Biology &#x00026; Medicine</copyright-holder><license license-type="open-access"><license-p>This work is licensed under a Creative Commons Attribution 3.0 Unported License. To view a copy of this license, visit
<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/3.0/">http://creativecommons.org/licenses/by/3.0/</ext-link></license-p></license></permissions><abstract><p>Long non-coding RNAs (lncRNAs) refer to a group of RNAs that are usually more than 200 nucleotides and are not involved in protein generation. Instead, lncRNAs are involved in different regulatory processes, such as regulation of gene expression. Different lncRNAs exist throughout the genome. LncRNAs are also known for their roles in different human diseases such as cancer. <italic>HOTAIR</italic> is an lncRNA that plays a role as an oncogenic molecule in different cancer cells, such as breast, gastric, colorectal, and cervical cancer cells. Therefore, <italic>HOTAIR</italic> expression level is a potential biomarker for diagnostic and therapeutic purposes in several cancers. This RNA takes part in epigenetic regulation of genes and plays an important role in different cellular pathways by interacting with Polycomb Repressive Complex 2 (PRC2). In this review, we describe the molecular function and regulation of <italic>HOTAIR</italic> and its role in different types of cancers.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS </title><kwd><italic>HOTAIR</italic></kwd><kwd>long non-coding RNA (lncRNA)</kwd><kwd>epigenetic</kwd><kwd>cancer</kwd></kwd-group></article-meta></front><body><sec sec-type="intro"><title>Introduction</title><p>The physiological and developmental complications of humans lead us to the point that the limited number of protein-coding genes compared with whole genome cannot explain the complexity of human features<xref rid="r1" ref-type="bibr"><sup>1</sup></xref>. Most of the genomic DNAs (at least 70%-90%) are transcribed to the RNAs that do not produce any proteins. These parts of the genomes are known as non-coding RNA (ncRNA) genes, which produce efficient RNA molecules<xref rid="r1" ref-type="bibr"><sup>1</sup></xref><sup>-</sup><xref rid="r4" ref-type="bibr"><sup>4</sup></xref>.</p><p>LncRNAs consist of a group of ncRNAs, including thousands of various species<xref rid="r5" ref-type="bibr"><sup>5</sup></xref>. These RNAs are usually more than 200 nucleotides and are mostly transcribed by RNA pol II from different regions across the genome. They play different roles such as transcriptional and post-transcriptional regulation inside the cell. Recently, lncRNAs are known as key regulators of gene expression<xref rid="r6" ref-type="bibr"><sup>6</sup></xref><sup>-</sup><xref rid="r8" ref-type="bibr"><sup>8</sup></xref>. By working on embryonic stem cells and through analyzing the ribosome profiling data, Chew <italic>et al</italic>.<xref rid="r9" ref-type="bibr"><sup>9</sup></xref> revealed that many lncRNAs are protein-coding contaminants. LncRNAs also regulate the activity of epigenetic machinery during cell differentiation<xref rid="r10" ref-type="bibr"><sup>10</sup></xref>. In fact, many lncRNAs recruit chromatin-modifying proteins (e.g., PRC2) to specific sites of genome and affect gene expression through regulating chromatin states<xref rid="r11" ref-type="bibr"><sup>11</sup></xref>.</p><p>Based on their roles, the dysregulation of lncRNAs is involved in several diseases including cancer<xref rid="r12" ref-type="bibr"><sup>12</sup></xref><sup>,</sup><xref rid="r13" ref-type="bibr"><sup>13</sup></xref>. Du <italic>et al</italic>.<xref rid="r14" ref-type="bibr"><sup>14</sup></xref> analyzed the expression of different lncRNAs in various tumors. Through this analysis, they identified the lncRNAs related to different cancers and their clinical prognosis. Dysregulation of lncRNAs is related to prognosis, metastasis, and recurrence in different cancer types. Studies show that dysregulation of certain lncRNAs affect several processes related to oncogenesis, including cell growth and proliferation<xref rid="r15" ref-type="bibr"><sup>15</sup></xref>. The over expression of some lncRNAs with proto-oncogenic function in normal cells increases tumor growth and matrix invasion of cancer cells<xref rid="r14" ref-type="bibr"><sup>14</sup></xref><sup>,</sup><xref rid="r16" ref-type="bibr"><sup>16</sup></xref>. Moreover, over-expression of oncogenic lncRNAs results in tumor-cell proliferation and metastasis through chromatin looping and some other processes<xref rid="r17" ref-type="bibr"><sup>17</sup></xref>.</p><p>In this review, we describe the oncogenic roles of <italic>HOTAIR</italic> long-non coding RNA as one of the most important regulatory RNAs in human cells. We also present the molecular function and regulation of this lncRNA in different types of cancer.</p></sec><sec><title><italic>HOTAIR</italic> lncRNA</title><p><italic>HOTAIR</italic> lncRNA was introduced by Rinn <italic>et al</italic>.<xref rid="r18" ref-type="bibr"><sup>18</sup></xref> as a spliced and polyadenylated RNA with 2,158 nucleotides and 6 exons. This RNA arises from the transcription of antisense strand of <italic>HoxC</italic> gene, which is specifically situated between <italic>HoxC11</italic> and <italic>HoxC12</italic> on chromosome 12q13.13. Computational and Northern blot analysis revealed that <italic>HOTAIR</italic> does not show any stem loops suggestive of being a pre-miRNA. These analysis also suggested that <italic>HOTAIR</italic> is preferentially expressed in posterior and distal sites of the human body. In an experiment on 10 mammalian genomes and 3 non-mammalian vertebrates, He <italic>et al</italic>.<xref rid="r19" ref-type="bibr"><sup>19</sup></xref> looked for matches to the 6 exons of <italic>HOTAIR</italic> and its two conserved domains. They reported a poor sequence conservation and, by contrast, noticeably conserved structures for <italic>HOTAIR</italic>. They also reported that <italic>HOTAIR</italic> has evolved faster compared with adjacent HoxC genes.</p><p><italic>HOTAIR</italic> is a trans-acting lncRNA and has different target loci such as HOXD<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>. <italic>HOTAIR</italic> interacts with Polycomb Repressive Complex 2 (PRC2) and is necessary for PRC2 occupancy and histone H3 lysine-27 trimethylation of different genes in different chromosomes. PRC2 is a histone methyltransferase that implements epigenetic silencing during different processes including cancer development<xref rid="r20" ref-type="bibr"><sup>20</sup></xref>. <italic>HOTAIR</italic> localizes and targets PRC2 genome wide<xref rid="r21" ref-type="bibr"><sup>21</sup></xref>. PRC2 is a complex that contains three major subunits, including EZH2, SUZ12, and EED. Although EZH2 is the key player for the methyltransfer process, other subunits are also required to regulate EZH2 catalytic activity<xref rid="r22" ref-type="bibr"><sup>22</sup></xref>. The affinity of EZH2 to RNA is regulated by EED, which increases the specificity of PRC2 function. Cifuentes-Rojas <italic>et al</italic>.<xref rid="r23" ref-type="bibr"><sup>23</sup></xref> investigated the PRC2-RNA interaction precisely. They showed that RNA directs PRC2 to its target gene and simultaneously inhibits the enzymatic activity of EZH2. When PRC2 reaches its target gene, JARID2 binds to EZH2 to impair PRC2&#x02019;s binding to RNA and thereby activates EZH2&#x02019;s function (<xref ref-type="fig" rid="f1"><bold>Figure 1</bold></xref>). Knockdown of JARID2 results in reduction of H3K27me3 levels on some target genes<xref rid="r24" ref-type="bibr"><sup>24</sup></xref>. JARID2 also may have a negative impact on PRC2&#x02019;s function, and deletion of JARID2 results in the enhancement of H3K27me3 levels on some target genes<xref rid="r25" ref-type="bibr"><sup>25</sup></xref>. <italic>HOTAIR</italic> functions as a molecular scaffold and interacts not only with PRC2 but also with LSD1 complex to regulate gene expression. LSD1 involves in demethylation of histone H3 at lysine 4<xref rid="r26" ref-type="bibr"><sup>26</sup></xref><sup>,</sup><xref rid="r27" ref-type="bibr"><sup>27</sup></xref> (<xref ref-type="fig" rid="f2"><bold>Figure 2</bold></xref>). Specifically, PRC2 binds to a 5' domain and LSD1 to a 3' domain of <italic>HOTAIR</italic>, and <italic>HOTAIR</italic> coordinates their functions for chromatin modification<xref rid="r28" ref-type="bibr"><sup>28</sup></xref>. Through these functions, <italic>HOTAIR</italic> affects the expression of multiple genes involved in various cellular functions<xref rid="r21" ref-type="bibr"><sup>21</sup></xref>.</p><fig id="f1" fig-type="figure" orientation="portrait" position="float"><label>Figure 1</label><caption><p>The RNAs recruiting PRC2 complex inhibit PRC2 function. These RNAs guide PRC2 to its target gene and inhibits EZH2 enzymatic activity at the same time. When PRC2 reaches its target gene, another protein called JARID2 comes into play and binds to EZH2, weakens EZH2-RNA binding, and consequently activates EZH2&#x02019;s function.</p></caption><graphic xlink:href="cbm-12-01-001-f1"/></fig><fig id="f2" fig-type="figure" orientation="portrait" position="float"><label>Figure 2</label><caption><p><italic>HOTAIR</italic> gene is located on chromosome 12 inside the <italic>HoxC</italic> locus, specifically between <italic>HoxC11</italic> and <italic>HoxC12</italic>. After the expression of <italic>HOTAIR</italic>, this lncRNA recruits PRC2 and LSD1 complexes and thus functions as a bridge. <italic>HOTAIR</italic> directs these complexes to their target genes and as a result regulates the trimethylation of H3K27 and demethylation of H3K4 at targeted genes. H3K27me3 and H3K4deme refer to the trimethylation of histone H3 at lysine-27 and the demethylation of histone H3 at lysine 4, respectively.</p></caption><graphic xlink:href="cbm-12-01-001-f2"/></fig></sec><sec><title><italic>HOTAIR</italic> lncRNA as an oncogenic factor in different cancers</title><p><italic>HOTAIR</italic> is an oncogenic factor and can be used as a prognostic biomarker in different cancer types<xref rid="r29" ref-type="bibr"><sup>29</sup></xref>. <italic>HOTAIR</italic> lncRNA plays a key role in the initiation and progression of different types of cancer such as cervical cancer and nasopharyngeal carcinoma<xref rid="r30" ref-type="bibr"><sup>30</sup></xref><sup>,</sup><xref rid="r31" ref-type="bibr"><sup>31</sup></xref>. <italic>HOTAIR</italic> also plays an important role in promoting malignancy<xref rid="r32" ref-type="bibr"><sup>32</sup></xref>. To assess the association between <italic>HOTAIR</italic> expression levels and lymph node metastasis, Cai <italic>et al</italic>.<xref rid="r33" ref-type="bibr"><sup>33</sup></xref> in a meta-analysis surveyed a total of 748 patients from 8 studies. In this meta-analysis, they showed that the patients with high <italic>HOTAIR</italic> expression level had a higher incidence compared with that in patients with low <italic>HOTAIR</italic> expression level. Moreover, Alves <italic>et al</italic>.<xref rid="r34" ref-type="bibr"><sup>34</sup></xref> investigated the role of <italic>HOTAIR</italic> in epithelial-to-mesenchymal transition (EMT) and also its role in arising and maintenance of cancer stem cells (CSCs). They revealed that <italic>HOTAIR</italic> plays an important role in the process of tumorigenicity by triggering EMT and acquiring stemness.</p><p>In fact, <italic>HOTAIR</italic> is involved in several processes associated with carcinogenesis such as those affecting the mobility, proliferation, apoptosis, invasion, aggression, and metastasis of the cells (<xref ref-type="table" rid="t1"><bold>Table 1</bold></xref>). PRC2 and LSD1 complexes to exert epigenetic modifications and suppressing a number of genes such as tumor and metastasis suppressor genes. Given these crucial functions, <italic>HOTAIR</italic> is applied as a potential biomarker of various human cancers. In addition, measuring the expression level of <italic>HOTAIR</italic> can help us detect the progression stage of cancer and predict the survival possibility of an individual<xref rid="r21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="r27" ref-type="bibr"><sup>27</sup></xref><sup>,</sup><xref rid="r38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="r39" ref-type="bibr"><sup>39</sup></xref>. Furthermore, <italic>HOTAIR</italic> is involved in the resistance of cancer cells to cisplatin. This role of <italic>HOTAIR</italic> is at least attributed to the downregulation of <italic>P21</italic> gene. Liu <italic>et al</italic>.<xref rid="r60" ref-type="bibr"><sup>60</sup></xref> found that knockdown of <italic>HOTAIR</italic> could resensitize the responses of A549/DDP cells to cisplatin. Interestingly, different functional SNPs across whole <italic>HOTAIR</italic> locus have been reported to influence the cancer risk<xref rid="r61" ref-type="bibr"><sup>61</sup></xref>.</p><table-wrap id="t1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Overexpression of <italic>HOTAIR</italic> in different cancers</title></caption><table frame="hsides" rules="groups"><col width="30.11%" span="1"/><col width="59.28%" span="1"/><col width="10.61%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Type</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Overexpression of <italic>HOTAIR</italic></th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Breast cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, metastasis, invasion, and short overall survival</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="r35" ref-type="bibr"><sup>35</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Esophageal squamous cell carcinoma (ESCC)</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, high TNM stage, invasion, metastasis, and short overall survival</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r36" ref-type="bibr"><sup>36</sup></xref><sup>,</sup><xref rid="r37" ref-type="bibr"><sup>37</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gastric cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Tumor staging, venous infiltration, and lymph node metastasis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r38" ref-type="bibr"><sup>38</sup></xref><sup>,</sup><xref rid="r39" ref-type="bibr"><sup>39</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Hepatocellular carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Invasion of HCC cells, possibility of recurrence</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r40" ref-type="bibr"><sup>40</sup></xref><sup>-</sup><xref rid="r44" ref-type="bibr"><sup>44</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Colorectal cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, low survival, and metastasis promotion</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r45" ref-type="bibr"><sup>45</sup></xref><sup>-</sup><xref rid="r47" ref-type="bibr"><sup>47</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Gallbladder cancer (GBC)</td><td valign="top" align="left" rowspan="1" colspan="1">Promoting carcinogenesis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Bladder cancer (BC)</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis and high recurrence rate</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r48" ref-type="bibr"><sup>48</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Renal carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Proliferation, invasion, and promotion of tumor growth</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r49" ref-type="bibr"><sup>49</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Cervical cancer</td><td valign="top" align="left" rowspan="1" colspan="1">FIGO stage, aggression, and lymph node metastasis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r30" ref-type="bibr"><sup>30</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Epithelial ovarian cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, FIGO stage, lymph node metastasis, overall survival, and metastatic stage of EOC</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r50" ref-type="bibr"><sup>50</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Endometrial carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, lymph node metastasis, EC grade, and overall survival</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="r52" ref-type="bibr"><sup>52</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Invasion and metastasis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r53" ref-type="bibr"><sup>53</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Non-small cell lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Promotion of lymph node metastasis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r54" ref-type="bibr"><sup>54</sup></xref><sup>,</sup><xref rid="r55" ref-type="bibr"><sup>55</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Small-cell lung cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, proliferation and invasion</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r56" ref-type="bibr"><sup>56</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Nasopharyngeal carcinoma</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, overall survival, proliferation, invasion, and promotion of tumor stage</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r31" ref-type="bibr"><sup>31</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Melanoma</td><td valign="top" align="left" rowspan="1" colspan="1">Invasion and metastasis</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r57" ref-type="bibr"><sup>57</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Glioma</td><td valign="top" align="left" rowspan="1" colspan="1">Poor prognosis, cell cycle progression, and glioma grade</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r58" ref-type="bibr"><sup>58</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pancreatic cancer</td><td valign="top" align="left" rowspan="1" colspan="1">Proliferation and aggression of tumors</td><td valign="top" align="left" rowspan="1" colspan="1"><xref rid="r59" ref-type="bibr"><sup>59</sup></xref></td></tr></tbody></table></table-wrap></sec><sec><title>Regulation of <italic>HOTAIR</italic> through different pathways</title><p>The expression level of <italic>HOTAIR</italic> gene and the function of its transcript can be controlled by several factors (<xref ref-type="table" rid="t2"><bold>Table 2</bold></xref>). The DNA methylation pattern of downstream intergenic CpG island of <italic>HOTAIR</italic> may have an important effect on its expression level<xref rid="r62" ref-type="bibr"><sup>62</sup></xref>. Moreover, the post-synthetic methylation of some cytosines of <italic>HOTAIR</italic> has been reported. This post-synthetic methylation within or near important functional regions of <italic>HOTAIR</italic> may play an important role in the regulation of <italic>HOTAIR</italic> function<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>.</p><table-wrap id="t2" orientation="portrait" position="float"><label>Table 2</label><caption><title><italic>HOTAIR</italic> regulatory factors</title></caption><table frame="hsides" rules="groups"><col width="40.46%" span="1"/><col width="21.35%" span="1"/><col width="28.08%" span="1"/><col width="10.11%" span="1"/><thead><tr><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Factors</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Up/down-regulation</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">Regulatory level</th><th valign="middle" align="left" scope="col" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Methylation of downstream intergenic CpG island</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r62" ref-type="bibr"><sup>62</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Post-synthetic methylation</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Post-transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r4" ref-type="bibr"><sup>4</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Functional SNPs across <italic>HOTAIR</italic> locus</td><td valign="middle" align="left" rowspan="1" colspan="1">Up/downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional/ post-transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r61" ref-type="bibr"><sup>61</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">siRNA</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Post-transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r49" ref-type="bibr"><sup>49</sup></xref><sup>,</sup><xref rid="r51" ref-type="bibr"><sup>51</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">MiR-141</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Post-transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r32" ref-type="bibr"><sup>32</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Argonaute2 (Ago2)</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Post-transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r32" ref-type="bibr"><sup>32</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Osteopontin (OPN)</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r63" ref-type="bibr"><sup>63</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">IRF1</td><td valign="middle" align="left" rowspan="1" colspan="1">Downregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r63" ref-type="bibr"><sup>63</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">c-Myc</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r29" ref-type="bibr"><sup>29</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">TGF-&#x003b2;</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r4" ref-type="bibr"><sup>4</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Diethylstilbestrol (DES)</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r64" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Bisphenol-A (BPA)</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r64" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Estrogen receptors (ERs) and ER coregulators</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r64" ref-type="bibr"><sup>64</sup></xref></td></tr><tr><td valign="middle" align="left" scope="row" rowspan="1" colspan="1">Type I collagen (Col-1)</td><td valign="middle" align="left" rowspan="1" colspan="1">Upregulation</td><td valign="middle" align="left" rowspan="1" colspan="1">Transcriptional</td><td valign="middle" align="left" rowspan="1" colspan="1"><xref rid="r65" ref-type="bibr"><sup>65</sup></xref></td></tr></tbody></table></table-wrap><p>The function of <italic>HOTAIR</italic> can be suppressed by argonaute2 (Ago2) complex in the presence of microRNA-141 (<italic>miR-141</italic>). <italic>MiR-141</italic>, unlike <italic>HOTAIR</italic>, is a suppressor of tumorigenicity, invasiveness, and malignancy in several cancer types. <italic>MiR-141</italic> first binds to <italic>HOTAIR</italic> to suppress it, and Ago2 complex comes into play and cleaves the <italic>HOTAIR</italic><xref rid="r32" ref-type="bibr"><sup>32</sup></xref>.</p><p>A type of phosphoglycoprotein called osteopontin (OPN), which is an extracellular matrix protein, can transcriptionally activate and increase <italic>HOTAIR</italic> expression in cancer cells. Receptor CD44, a positive regulator of OPN, affects the expression level of <italic>HOTAIR</italic>. By contrast, interferon regulatory factor 1 (IRF1) decreases <italic>HOTAIR</italic> expression level by binding to its promoter. In fact, OPN regulates IRF1 and affects its signaling pathway, thus activating <italic>HOTAIR</italic> expression by suppressing the function of IRF1<xref rid="r63" ref-type="bibr"><sup>63</sup></xref>.</p><p>The protein c-Myc is another element that impacts the expression of <italic>HOTAIR</italic>. c-Myc is an oncoprotein that plays a role in the development of several types of cancer through regulating several protein-coding and non-coding genes. c-Myc recognizes a putative E-box element in the upstream region of <italic>HOTAIR</italic>, which is approximately located at the 1,053 upstream within its promoter. c-Myc directly interacts with this E-box element and upregulates the expression of <italic>HOTAIR</italic>. In addition, knockdown of c-Myc can reduce both <italic>HOTAIR</italic> expression and its promoter activity, whereas upregulation of c-<italic>Myc</italic> gene increases <italic>HOTAIR</italic> expression and its promoter activity<xref rid="r29" ref-type="bibr"><sup>29</sup></xref>. Moreover, silico analysis identified four potential Myc-binding sites within <italic>HOTAIR</italic> promoter<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>.</p><p>Researchers working on human breast cancer cells have shown that diethylstilbestrol and bisphenol-A can upregulate the expression of <italic>HOTAIR</italic> in these cells<xref rid="r66" ref-type="bibr"><sup>66</sup></xref>. Some evidence showed the existence of estrogen response elements in the promoter of <italic>HOTAIR</italic>. Estrogen receptors (ERs) and ER coregulators, such as histone methylases mixed lineage leukemia (MLL) 1, MLL3, and CREB-binding protein/p300, induce the expression of <italic>HOTAIR</italic> by binding to its promoter<xref rid="r64" ref-type="bibr"><sup>64</sup></xref>.</p><p>TGF-&#x003b2; is another factor that induces <italic>HOTAIR</italic> expression and involves in EMT, which results in arising and maintenance of CSCs<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>. Furthermore, evidence suggests the effect of type I collagen (Col-1) on <italic>HOTAIR</italic> upregulation. Zhuang <italic>et al</italic>.<xref rid="r65" ref-type="bibr"><sup>65</sup></xref> showed that Col-1, which is aberrantly enriched in the tumor microenvironment, can induce the expression of <italic>HOTAIR</italic> in lung cancer cells<xref rid="r53" ref-type="bibr"><sup>53</sup></xref>. In addition, <italic>HOTAIR</italic> overexpression has been reported in non-small cell lung cancer<xref rid="r54" ref-type="bibr"><sup>54</sup></xref>.</p></sec><sec><title><italic>HOTAIR</italic> functions</title><sec><title>Coordination with PRC2</title><p>Li <italic>et al</italic>.<xref rid="r26" ref-type="bibr"><sup>26</sup></xref> showed that directed deletion of <italic>HOTAIR</italic> lncRNA in mouse can result in activation of hundreds of genes. Different downstream pathways and genes are attributed to the molecular roles of <italic>HOTAIR</italic> in human cells. <italic>HOTAIR</italic> can act through promoting the chromatin relocalization done by PRC2. This targeting of PRC2 in the genome leads into a distinct pattern of gene expression necessary for breast cancer progression<xref rid="r21" ref-type="bibr"><sup>21</sup></xref><sup>,</sup><xref rid="r35" ref-type="bibr"><sup>35</sup></xref>. Specifically, an overlap exists between <italic>HOTAIR</italic>-binding motif and BRCA1-binding region in EZH2. This finding indicates that decreased expression of BRCA1 results in elevated recruitment of PRC2 by <italic>HOTAIR</italic> in breast cancer cell lines<xref rid="r4" ref-type="bibr"><sup>4</sup></xref>.</p></sec><sec><title><italic>HOTAIR</italic> functions through Wnt/&#x003b2;-catenin</title><p>The key role of <italic>HOTAIR</italic> in the development and progression of esophageal squamous cell carcinoma (ESCC) has been revealed<xref rid="r36" ref-type="bibr"><sup>36</sup></xref>. <italic>HOTAIR</italic> exerts its role through activating Wnt/&#x003b2;-catenin signaling pathway. The Wnt/&#x003b2;-catenin signaling pathway is an important pathway in the development of ESCC. <italic>HOTAIR</italic> recruits PRC2 directly to the promoter region of <italic>Wnt inhibitory factor 1</italic> (<italic>WIF-1</italic>), leading to the reduction of <italic>WIF-1</italic> expression and consequently the activation of Wnt/&#x003b2;-catenin signaling pathway<xref rid="r37" ref-type="bibr"><sup>37</sup></xref><sup>,</sup><xref rid="r61" ref-type="bibr"><sup>61</sup></xref>. In addition, different functional SNPs across the whole <italic>HOTAIR</italic> locus that affects the regulation of <italic>HOTAIR</italic> may influence ESCC risk<xref rid="r61" ref-type="bibr"><sup>61</sup></xref>.</p></sec><sec><title>Involvement in EMT</title><p>Through a series of <italic>in vitro</italic> and <italic>in vivo</italic> assays on epithelial ovarian cancer (EOC) tissues, researchers showed that a significant association exists between <italic>HOTAIR</italic> expression level and metastatic stage of EOC. This association may be due to the regulation of certain matrix metalloproteinases (MMPs) and EMT-related genes by <italic>HOTAIR</italic>. <italic>HOTAIR</italic> expression is also associated with FIGO stage/metastasis of lymph nodes; thus, this factor could be a potential biomarker or therapeutic target in EOC patients<xref rid="r50" ref-type="bibr"><sup>50</sup></xref>.</p><p>Inhibition of <italic>HOTAIR</italic> in gastric cancer cells leads to EMT process reversal and reduction of invasiveness mediated by the expression of MMP1 and MMP3<xref rid="r67" ref-type="bibr"><sup>67</sup></xref>. Some evidence shows that suppression of <italic>miR-7</italic> by <italic>HOTAIR</italic> can mediate EMT progression in breast cancer. This microRNA can inhibit the SETDB1 and STAT3 pathway in breast cells<xref rid="r68" ref-type="bibr"><sup>68</sup></xref>.</p></sec><sec><title>Functions as competitive endogenous RNAs</title><p><italic>HOTAIR</italic> can function as competitive endogenous RNAs (ceRNAs) in gastric cells by recruiting the microRNAs targeting the HER-2. Thus, <italic>HOTAIR</italic> and HER-2 may have coexpression in gastric cancer tissues<xref rid="r69" ref-type="bibr"><sup>69</sup></xref>. Given this recently identified role of <italic>HOTAIR</italic>, the finding indicative of the positive interaction between <italic>HOTAIR</italic> and HER2 is worth to research in other types of cancer cells.</p><p><italic>miRNA-130a</italic> binding sites were found in <italic>HOTAIR</italic> lncRNA. A negative correlation between <italic>HOTAIR</italic> and <italic>miRNA-130a</italic> has been demonstrated in gallbladder cancer tissues compared with nearby normal tissues. Thus, the oncogenic role of <italic>HOTAIR</italic> is not only by recruiting PRC2 but also partly through negative regulation of <italic>miRNA-130a</italic><xref rid="r29" ref-type="bibr"><sup>29</sup></xref>.</p></sec><sec><title><italic>HOTAIR</italic> regulates various genes in tumors</title><p><italic>HOTAIR</italic> overexpression is also related to hepatocellular carcinoma (HCC)<xref rid="r40" ref-type="bibr"><sup>40</sup></xref><sup>-</sup><xref rid="r43" ref-type="bibr"><sup>43</sup></xref>. In an experiment, Ding <italic>et al</italic>.<xref rid="r44" ref-type="bibr"><sup>44</sup></xref> showed that suppression of <italic>HOTAIR</italic> leads to the increase of RNA binding motif 38 (RBM38) proteins, which play a role in the regulation of cell motility. They also showed that RBM38 expression levels were lower in HCC tissues compared with noncancerous tissues in the same patients. Therefore, <italic>HOTAIR</italic> increases the aggression and invasion of HCC cells by suppressing RBM38 expression.</p><p>Some reports indicate that <italic>HOTAIR</italic> plays an oncogenic role partially via the downregulation of <italic>HOXA5</italic><xref rid="r55" ref-type="bibr"><sup>55</sup></xref>. The results also suggest that this lncRNA plays a potential oncogenic role through influencing the expression of specific genes associated with cell adhesion such as <italic>MUC5AC</italic> and <italic>ASTN1</italic><xref rid="r56" ref-type="bibr"><sup>56</sup></xref>. Kogo <italic>et al</italic>.<xref rid="r45" ref-type="bibr"><sup>45</sup></xref> suggested that <italic>HOTAIR</italic> regulates the expression of multiple genes in cooperation with PRC2 and raises the levels of undifferentiated cancer cells in CRC patients.</p><p>In an experiment, Yan <italic>et al</italic>.<xref rid="r48" ref-type="bibr"><sup>48</sup></xref> measured the <italic>HOTAIR</italic> expression level of Ta/T1 bladder cancer tissues and adjacent normal tissues, which were collected from 110 patients. They reported that 90 specimens had high <italic>HOTAIR</italic> expression levels, which were inversely correlated with <italic>WIF-1</italic> expression. <italic>HOTAIR</italic> may also be involved in the development of colorectal cancer<xref rid="r46" ref-type="bibr"><sup>46</sup></xref><sup>,</sup><xref rid="r47" ref-type="bibr"><sup>47</sup></xref>.</p><p>Wu <italic>et al</italic>.<xref rid="r49" ref-type="bibr"><sup>49</sup></xref> reported an increase in <italic>HOTAIR</italic> expression level in renal carcinoma cells. They also reported that knockdown of <italic>HOTAIR</italic> by siRNA impacts the cell cycle in the G<sub>0</sub>/G<sub>1</sub> phase and also decreases the cell proliferation and invasion <italic>in vitro</italic>. These effects resulted in the reduction of <italic>HOTAIR</italic> binding ability to EZH2 and consequently the reduction of H3K27me3 on <italic>HOTAIR</italic> target genes. Furthermore, they showed that inhibition of <italic>HOTAIR</italic> expression resulted in suppression of growth of xenograft tumors formed by renal carcinoma cells. In addition, they demonstrated that inhibition of <italic>HOTAIR</italic> expression and modulation of covalent histones activated transcriptional state of cell cycle-related gene.</p><p>Tang <italic>et al</italic>.<xref rid="r57" ref-type="bibr"><sup>57</sup></xref> investigated the potential roles of <italic>HOTAIR</italic> in melanoma cells and showed that <italic>HOTAIR</italic> is overexpressed in metastatic melanoma tissues. They showed that knockdown of <italic>HOTAIR</italic> by siRNAs resulted in the reduction of motility and invasion of human melanoma cell line A375. They also reported that <italic>HOTAIR</italic> is involved in promoting gelatinase activity in melanoma cells.</p><p>Different studies revealed that increasing the expression of <italic>HOTAIR</italic> has several effects, such as increasing the proliferation and aggression of cancer cells in pancreatic cancer tissues. On the contrary, downregulation of <italic>HOTAIR</italic> has opposite effects, including inhibition of cell cycle progression, reducing proliferation, and increasing apoptosis. However, the results of gene array studies showed that some differences exist between <italic>HOTAIR</italic>-regulated genes in pancreatic cells and breast cancer cells. These studies suggest several interferon- and cell cycle-related genes as targets of <italic>HOTAIR</italic> in pancreatic cancer cells<xref rid="r59" ref-type="bibr"><sup>59</sup></xref>. Furthermore, overexpression of <italic>HOTAIR</italic> may be associated with endometrial carcinoma<xref rid="r51" ref-type="bibr"><sup>51</sup></xref><sup>,</sup><xref rid="r52" ref-type="bibr"><sup>52</sup></xref>.</p><p>Although the exact roles of <italic>HOTAIR</italic> in glioma and glioblastoma are still challenging, <italic>HOTAIR</italic> can be used as a prognostic biomarker in glioma<xref rid="r58" ref-type="bibr"><sup>58</sup></xref>.</p></sec></sec><sec sec-type="conclusions"><title>Conclusion</title><p>Different studies provide some evidence for the crucial roles of <italic>HOTAIR</italic> in the initiation and progression of various cancers. Understanding the biological roles of <italic>HOTAIR</italic> in different types of cancer helps us to determine the efficiency of this lncRNA as a diagnostic or predictive biomarker. However, <italic>HOTAIR</italic> has been suggested as a biomarker for most cancer types. Thus, conducting a meta-analysis of <italic>HOTAIR</italic> expression in all cancer types may help in the identification of the cancers that have the highest probability of <italic>HOTAIR</italic> overexpression. Hence, <italic>HOTAIR</italic> expression level can be used as a potential prognostic factor for various cancers. In addition, screening the <italic>HOTAIR</italic> overexpression can help us identify cancer progression and tumor stage. Expression analysis can be conducted by different quantitative techniques such as RT-PCR. These assays would be valuable when the RNA level can be differentially analyzed in samples of patients such as urine, blood, and mucus. However, clinical trials are needed in the future to find this RNA as a suitable biomarker or therapeutic target in cancer.</p><p><italic>HOTAIR</italic> can also be further considered as a therapeutic target to improve the sensitivity of therapy for different tumors. Moreover, the efficacy of these therapeutic approaches can be further expanded via identification of exact molecular pathways underlying the regulation of <italic>HOTAIR</italic> expression. Although some regulatory pathways of <italic>HOTAIR</italic> expression have been reported, thorough identification of those pathways requires more studies and experiments.</p></sec></body><back><fn-group><fn fn-type="conflict"><p>No potential conflicts of interest are disclosed.</p></fn></fn-group><ref-list><title>References</title><ref id="r1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Dinger</surname><given-names>ME</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group>. <article-title>Long non-coding RNAs: insights into functions.</article-title><source>Nat Rev Genet</source><year>2009</year>;<volume>10</volume>:<fpage>155</fpage>-<lpage>159</lpage>.<pub-id pub-id-type="pmid">19188922</pub-id></mixed-citation></ref><ref id="r2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>HJ</given-names></name><name><surname>Hsu</surname><given-names>JM</given-names></name><name><surname>Chang</surname><given-names>SS</given-names></name><name><surname>Labaff</surname><given-names>AM</given-names></name><name><surname>Li</surname><given-names>CW</given-names></name><etal/></person-group><article-title>Long non-coding RNAs: versatile master regulators of gene expression and crucial players in cancer.</article-title><source>Am J Transl Res</source><year>2012</year>;<volume>4</volume>:<fpage>127</fpage>-<lpage>150</lpage>.<pub-id pub-id-type="pmid">22611467</pub-id></mixed-citation></ref><ref id="r3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eddy</surname><given-names>SR</given-names></name></person-group>. <article-title>Non-coding RNA genes and the modern RNA world.</article-title><source>Nat Rev Genet</source><year>2001</year>;<volume>2</volume>:<fpage>919</fpage>-<lpage>929</lpage>.<pub-id pub-id-type="pmid">11733745</pub-id></mixed-citation></ref><ref id="r4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajjari</surname><given-names>M</given-names></name><name><surname>Khoshnevisan</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name></person-group>. <article-title>Molecular function and regulation of long non-coding RNAs: paradigms with potential roles in cancer.</article-title><source>Tumour Biol</source><year>2014</year>;<volume>35</volume>:<fpage>10645</fpage>-<lpage>10663</lpage>.<pub-id pub-id-type="pmid">25266799</pub-id></mixed-citation></ref><ref id="r5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fatica</surname><given-names>A</given-names></name><name><surname>Bozzoni</surname><given-names>I.</given-names></name></person-group><article-title>Long non-coding RNAs: new players in cell differentiation and development.</article-title><source>Nat Rev Genet</source><year>2014</year>;<volume>15</volume>:<fpage>7</fpage>-<lpage>21</lpage>.<pub-id pub-id-type="pmid">24296535</pub-id></mixed-citation></ref><ref id="r6"><label>6</label><mixed-citation publication-type="book">Kurokawa R. Long Noncoding RNA as a Regulator for Transcription. In: Ugarkovic D. eds. Long Non-Coding RNAs. Berlin, Heidelberg: Springer Berlin Heidelberg, 2011;51:29-41.</mixed-citation></ref><ref id="r7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Flynn</surname><given-names>RA</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group>. <article-title>Long noncoding RNAs in cell-fate programming and reprogramming.</article-title><source>Cell stem cell</source><year>2014</year>;<volume>14</volume>:<fpage>752</fpage>-<lpage>761</lpage>.<pub-id pub-id-type="pmid">24905165</pub-id></mixed-citation></ref><ref id="r8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eades</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>YS</given-names></name><name><surname>Li</surname><given-names>QL</given-names></name><name><surname>Xia</surname><given-names>JX</given-names></name><name><surname>Yao</surname><given-names>Y</given-names></name><name><surname>Zhou</surname><given-names>Q</given-names></name></person-group>. <article-title>Long non-coding RNAs in stem cells and cancer.</article-title><source>World J Clin Oncol</source><year>2014</year>;<volume>5</volume>:<fpage>134</fpage>-<lpage>141</lpage>.<pub-id pub-id-type="pmid">24829860</pub-id></mixed-citation></ref><ref id="r9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chew</surname><given-names>GL</given-names></name><name><surname>Pauli</surname><given-names>A</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Regev</surname><given-names>A</given-names></name><name><surname>Schier</surname><given-names>AF</given-names></name><name><surname>Valen</surname><given-names>E</given-names></name></person-group>. <article-title>Ribosome profiling reveals resemblance between long non-coding RNAs and 5&#x02019; leaders of coding RNAs.</article-title><source>Development</source><year>2013</year>;<volume>140</volume>:<fpage>2828</fpage>-<lpage>2834</lpage>.<pub-id pub-id-type="pmid">23698349</pub-id></mixed-citation></ref><ref id="r10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinn</surname><given-names>JL</given-names></name></person-group>. <article-title>lncRNAs: linking RNA to chromatin.</article-title><source>Cold Spring Harb Perspect Biol</source><year>2014</year>;<volume>6</volume>. pii: <fpage>a018614</fpage>.<pub-id pub-id-type="pmid">25085913</pub-id></mixed-citation></ref><ref id="r11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mercer</surname><given-names>TR</given-names></name><name><surname>Mattick</surname><given-names>JS</given-names></name></person-group>. <article-title>Structure and function of long noncoding RNAs in epigenetic regulation.</article-title><source>Nat Struct Mol Biol</source><year>2013</year>;<volume>20</volume>:<fpage>300</fpage>-<lpage>307</lpage>.<pub-id pub-id-type="pmid">23463315</pub-id></mixed-citation></ref><ref id="r12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wapinski</surname><given-names>O</given-names></name><name><surname>Chang</surname><given-names>HY</given-names></name></person-group>. <article-title>Long noncoding RNAs and human disease.</article-title><source>Trends Cell Biol</source><year>2011</year>;<volume>21</volume>:<fpage>354</fpage>-<lpage>361</lpage>.<pub-id pub-id-type="pmid">21550244</pub-id></mixed-citation></ref><ref id="r13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajjari</surname><given-names>M</given-names></name><name><surname>Khoshnevisan</surname><given-names>A</given-names></name><name><surname>Shin</surname><given-names>YK</given-names></name></person-group>. <article-title>Long non-coding RNAs in hematologic malignancies: road to translational research.</article-title><source>Front Genet</source><year>2013</year>;<volume>4</volume>:<fpage>250</fpage>.<pub-id pub-id-type="pmid">24312125</pub-id></mixed-citation></ref><ref id="r14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Du</surname><given-names>Z</given-names></name><name><surname>Fei</surname><given-names>T</given-names></name><name><surname>Verhaak</surname><given-names>RG</given-names></name><name><surname>Su</surname><given-names>Z</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><etal/></person-group><article-title>Integrative genomic analyses reveal clinically relevant long noncoding RNAs in human cancer.</article-title><source>Nat Struct Mol Biol</source><year>2013</year>;<volume>20</volume>:<fpage>908</fpage>-<lpage>913</lpage>.<pub-id pub-id-type="pmid">23728290</pub-id></mixed-citation></ref><ref id="r15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Martens-Uzunova</surname><given-names>ES</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>R</given-names></name><name><surname>Croce</surname><given-names>CM</given-names></name><name><surname>Jenster</surname><given-names>G</given-names></name><name><surname>Visakorpi</surname><given-names>T</given-names></name><name><surname>Calin</surname><given-names>GA</given-names></name></person-group>. <article-title>Long noncoding RNA in prostate, bladder, and kidney cancer.</article-title><source>Eur Urol</source><year>2014</year>;<volume>65</volume>:<fpage>1140</fpage>-<lpage>1151</lpage>.<pub-id pub-id-type="pmid">24373479</pub-id></mixed-citation></ref><ref id="r16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>MT</given-names></name><name><surname>Hu</surname><given-names>JW</given-names></name><name><surname>Yin</surname><given-names>R</given-names></name><name><surname>Xu</surname><given-names>L</given-names></name></person-group>. <article-title>Long noncoding RNA: an emerging paradigm of cancer research.</article-title><source>Tumour Biol</source><year>2013</year>;<volume>34</volume>:<fpage>613</fpage>-<lpage>620</lpage>.<pub-id pub-id-type="pmid">23359273</pub-id></mixed-citation></ref><ref id="r17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Walsh</surname><given-names>AL</given-names></name><name><surname>Tuzova</surname><given-names>AV</given-names></name><name><surname>Bolton</surname><given-names>EM</given-names></name><name><surname>Lynch</surname><given-names>TH</given-names></name><name><surname>Perry</surname><given-names>AS</given-names></name></person-group>. <article-title>Long noncoding RNAs and prostate carcinogenesis: the missing &#x02018;linc&#x02019;?</article-title><source>Trends in molecular medicine</source><year>2014</year>;<volume>20</volume>:<fpage>428</fpage>-<lpage>436</lpage>.<pub-id pub-id-type="pmid">24836411</pub-id></mixed-citation></ref><ref id="r18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Kertesz</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Squazzo</surname><given-names>SL</given-names></name><name><surname>Xu</surname><given-names>X</given-names></name><name><surname>Brugmann</surname><given-names>SA</given-names></name><etal/></person-group><article-title>Functional demarcation of active and silent chromatin domains in human HOX loci by noncoding RNAs.</article-title><source>Cell</source><year>2007</year>;<volume>129</volume>:<fpage>1311</fpage>-<lpage>1323</lpage>.<pub-id pub-id-type="pmid">17604720</pub-id></mixed-citation></ref><ref id="r19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Zhu</surname><given-names>H.</given-names></name></person-group><article-title>The sequence, structure and evolutionary features of HOTAIR in mammals.</article-title><source>BMC Evol Biol</source><year>2011</year>;<volume>11</volume>:<fpage>102</fpage>.<pub-id pub-id-type="pmid">21496275</pub-id></mixed-citation></ref><ref id="r20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidovich</surname><given-names>C</given-names></name><name><surname>Zheng</surname><given-names>L</given-names></name><name><surname>Goodrich</surname><given-names>KJ</given-names></name><name><surname>Cech</surname><given-names>TR</given-names></name></person-group>. <article-title>Promiscuous RNA binding by Polycomb repressive complex 2.</article-title><source>Nat Struct Mol Biol</source><year>2013</year>;<volume>20</volume>:<fpage>1250</fpage>-<lpage>1257</lpage>.<pub-id pub-id-type="pmid">24077223</pub-id></mixed-citation></ref><ref id="r21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gupta</surname><given-names>RA</given-names></name><name><surname>Shah</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>KC</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Horlings</surname><given-names>HM</given-names></name><name><surname>Wong</surname><given-names>DJ</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis.</article-title><source>Nature</source><year>2010</year>;<volume>464</volume>:<fpage>1071</fpage>-<lpage>1076</lpage>.<pub-id pub-id-type="pmid">20393566</pub-id></mixed-citation></ref><ref id="r22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>H</given-names></name><name><surname>Zeng</surname><given-names>H</given-names></name><name><surname>Dong</surname><given-names>A</given-names></name><name><surname>Li</surname><given-names>F</given-names></name><name><surname>He</surname><given-names>H</given-names></name><name><surname>Senisterra</surname><given-names>G</given-names></name><etal/></person-group><article-title>Structure of the catalytic domain of EZH2 reveals conformational plasticity in cofactor and substrate binding sites and explains oncogenic mutations.</article-title><source>PloS one</source><year>2013</year>;<volume>8</volume>:<fpage>e83737</fpage>.<pub-id pub-id-type="pmid">24367611</pub-id></mixed-citation></ref><ref id="r23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cifuentes-Rojas</surname><given-names>C</given-names></name><name><surname>Hernandez</surname><given-names>AJ</given-names></name><name><surname>Sarma</surname><given-names>K</given-names></name><name><surname>Lee</surname><given-names>JT</given-names></name></person-group>. <article-title>Regulatory interactions between RNA and polycomb repressive complex 2.</article-title><source>Mol Cell</source><year>2014</year>;<volume>55</volume>:<fpage>171</fpage>-<lpage>185</lpage>.<pub-id pub-id-type="pmid">24882207</pub-id></mixed-citation></ref><ref id="r24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pasini</surname><given-names>D</given-names></name><name><surname>Cloos</surname><given-names>PA</given-names></name><name><surname>Walfridsson</surname><given-names>J</given-names></name><name><surname>Olsson</surname><given-names>L</given-names></name><name><surname>Bukowski</surname><given-names>JP</given-names></name><name><surname>Johansen</surname><given-names>JV</given-names></name><etal/></person-group><article-title>JARID2 regulates binding of the Polycomb repressive complex 2 to target genes in ES cells.</article-title><source>Nature</source><year>2010</year>;<volume>464</volume>:<fpage>306</fpage>-<lpage>310</lpage>.<pub-id pub-id-type="pmid">20075857</pub-id></mixed-citation></ref><ref id="r25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herz</surname><given-names>HM</given-names></name><name><surname>Shilatifard</surname><given-names>A</given-names></name></person-group>. <article-title>The JARID2-PRC2 duality.</article-title><source>Genes Dev</source><year>2010</year>;<volume>24</volume>:<fpage>857</fpage>-<lpage>861</lpage>.<pub-id pub-id-type="pmid">20439426</pub-id></mixed-citation></ref><ref id="r26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Wapinski</surname><given-names>OL</given-names></name><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Qu</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>J</given-names></name><etal/></person-group><article-title>Targeted disruption of Hotair leads to homeotic transformation and gene derepression.</article-title><source>Cell Rep</source><year>2013</year>;<volume>5</volume>:<fpage>3</fpage>-<lpage>12</lpage>.<pub-id pub-id-type="pmid">24075995</pub-id></mixed-citation></ref><ref id="r27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Zhang</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Ren</surname><given-names>X</given-names></name><name><surname>Wei</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long noncoding RNA HOTAIR involvement in cancer.</article-title><source>Tumour Biol</source><year>2014</year>;<volume>35</volume>:<fpage>9531</fpage>-<lpage>9538</lpage>.<pub-id pub-id-type="pmid">25168368</pub-id></mixed-citation></ref><ref id="r28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsai</surname><given-names>MC</given-names></name><name><surname>Manor</surname><given-names>O</given-names></name><name><surname>Wan</surname><given-names>Y</given-names></name><name><surname>Mosammaparast</surname><given-names>N</given-names></name><name><surname>Wang</surname><given-names>JK</given-names></name><name><surname>Lan</surname><given-names>F</given-names></name><etal/></person-group><article-title>Long noncoding RNA as modular scaffold of histone modification complexes.</article-title><source>Science</source><year>2010</year>;<volume>329</volume>:<fpage>689</fpage>-<lpage>693</lpage>.<pub-id pub-id-type="pmid">20616235</pub-id></mixed-citation></ref><ref id="r29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ma</surname><given-names>MZ</given-names></name><name><surname>Li</surname><given-names>CX</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name><name><surname>Weng</surname><given-names>MZ</given-names></name><name><surname>Zhang</surname><given-names>MD</given-names></name><name><surname>Qin</surname><given-names>YY</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR, a c-Myc activated driver of malignancy, negatively regulates miRNA-130a in gallbladder cancer.</article-title><source>Mol Cancer</source><year>2014</year>;<volume>13</volume>:<fpage>156</fpage>.<pub-id pub-id-type="pmid">24953832</pub-id></mixed-citation></ref><ref id="r30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>L</given-names></name><name><surname>Liao</surname><given-names>LM</given-names></name><name><surname>Liu</surname><given-names>AW</given-names></name><name><surname>Wu</surname><given-names>JB</given-names></name><name><surname>Cheng</surname><given-names>XL</given-names></name><name><surname>Lin</surname><given-names>JX</given-names></name><etal/></person-group><article-title>Overexpression of long noncoding RNA HOTAIR predicts a poor prognosis in patients with cervical cancer.</article-title><source>Arch Gynecol Obstet</source><year>2014</year>;<volume>290</volume>:<fpage>717</fpage>-<lpage>723</lpage>.<pub-id pub-id-type="pmid">24748337</pub-id></mixed-citation></ref><ref id="r31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nie</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>X</given-names></name><name><surname>Qu</surname><given-names>S</given-names></name><name><surname>Song</surname><given-names>E</given-names></name><name><surname>Zou</surname><given-names>H</given-names></name></person-group>, <article-title>Gong Cet al. Long non-coding RNA HOTAIR is an independent prognostic marker for nasopharyngeal carcinoma progression and survival.</article-title><source>Cancer Sci</source><year>2013</year>;<volume>104</volume>:<fpage>458</fpage>-<lpage>464</lpage>.<pub-id pub-id-type="pmid">23281836</pub-id></mixed-citation></ref><ref id="r32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chiyomaru</surname><given-names>T</given-names></name><name><surname>Fukuhara</surname><given-names>S</given-names></name><name><surname>Saini</surname><given-names>S</given-names></name><name><surname>Majid</surname><given-names>S</given-names></name><name><surname>Deng</surname><given-names>G</given-names></name><name><surname>Shahryari</surname><given-names>V</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR is targeted and regulated by miR-141 in human cancer cells.</article-title><source>J Biol Chem</source><year>2014</year>;<volume>289</volume>:<fpage>12550</fpage>-<lpage>12565</lpage>.<pub-id pub-id-type="pmid">24616104</pub-id></mixed-citation></ref><ref id="r33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cai</surname><given-names>B</given-names></name><name><surname>Wu</surname><given-names>Z</given-names></name><name><surname>Liao</surname><given-names>K</given-names></name><name><surname>Zhang</surname><given-names>S.</given-names></name></person-group><article-title>Long noncoding RNA HOTAIR can serve as a common molecular marker for lymph node metastasis: a meta-analysis.</article-title><source>Tumour Biol</source><year>2014</year>;<volume>35</volume>:<fpage>8445</fpage>-<lpage>8450</lpage>.<pub-id pub-id-type="pmid">25017366</pub-id></mixed-citation></ref><ref id="r34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>P&#x000e1;dua Alves</surname><given-names>C</given-names></name><name><surname>Fonseca</surname><given-names>AS</given-names></name><name><surname>Muys</surname><given-names>BR</given-names></name></person-group>, de Barros E Lima Bueno R, B&#x000fc;rger MC, de Souza JE, et al. <article-title>Brief report: The lincRNA Hotair is required for epithelial-to-mesenchymal transition and stemness maintenance of cancer cell lines.</article-title><source>Stem Cells</source><year>2013</year>;<volume>31</volume>:<fpage>2827</fpage>-<lpage>2832</lpage>.<pub-id pub-id-type="pmid">24022994</pub-id></mixed-citation></ref><ref id="r35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>S&#x000f8;rensen</surname><given-names>KP</given-names></name><name><surname>Thomassen</surname><given-names>M</given-names></name><name><surname>Tan</surname><given-names>Q</given-names></name><name><surname>Bak</surname><given-names>M</given-names></name><name><surname>Cold</surname><given-names>S</given-names></name><name><surname>Burton</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR is an independent prognostic marker of metastasis in estrogen receptor-positive primary breast cancer.</article-title><source>Breast Cancer Res Treat</source><year>2013</year>;<volume>142</volume>:<fpage>529</fpage>-<lpage>536</lpage>.<pub-id pub-id-type="pmid">24258260</pub-id></mixed-citation></ref><ref id="r36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>FJ</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>SQ</given-names></name><name><surname>Wu</surname><given-names>QQ</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>ZL</given-names></name><etal/></person-group><article-title>Upregulation of the long non-coding RNA HOTAIR promotes esophageal squamous cell carcinoma metastasis and poor prognosis.</article-title><source>Mol Carcinog</source><year>2013</year>;<volume>52</volume>:<fpage>908</fpage>-<lpage>915</lpage>.<pub-id pub-id-type="pmid">24151120</pub-id></mixed-citation></ref><ref id="r37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ge</surname><given-names>XS</given-names></name><name><surname>Ma</surname><given-names>HJ</given-names></name><name><surname>Zheng</surname><given-names>XH</given-names></name><name><surname>Ruan</surname><given-names>HL</given-names></name><name><surname>Liao</surname><given-names>XY</given-names></name><name><surname>Xue</surname><given-names>WQ</given-names></name><etal/></person-group><article-title>HOTAIR, a prognostic factor in esophageal squamous cell carcinoma, inhibits WIF-1 expression and activates Wnt pathway.</article-title><source>Cancer Sci</source><year>2013</year>;<volume>104</volume>:<fpage>1675</fpage>-<lpage>1682</lpage>.<pub-id pub-id-type="pmid">24118380</pub-id></mixed-citation></ref><ref id="r38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hajjari</surname><given-names>M</given-names></name><name><surname>Behmanesh</surname><given-names>M</given-names></name><name><surname>Sadeghizadeh</surname><given-names>M</given-names></name><name><surname>Zeinoddini</surname><given-names>M.</given-names></name></person-group><article-title>Up-regulation of HOTAIR long non-coding RNA in human gastric adenocarcinoma tissues.</article-title><source>Med Oncol</source><year>2013</year>;<volume>30</volume>:<fpage>670</fpage>.<pub-id pub-id-type="pmid">23888369</pub-id></mixed-citation></ref><ref id="r39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Shiroki</surname><given-names>T</given-names></name><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Yamanami</surname><given-names>H</given-names></name><etal/></person-group><article-title>Enhanced expression of long non-coding RNA HOTAIR is associated with the development of gastric cancer.</article-title><source>PloS one</source><year>2013</year>;<volume>8</volume>:<fpage>e77070</fpage>.<pub-id pub-id-type="pmid">24130837</pub-id></mixed-citation></ref><ref id="r40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Geng</surname><given-names>YJ</given-names></name><name><surname>Xie</surname><given-names>SL</given-names></name><name><surname>Li</surname><given-names>Q</given-names></name><name><surname>Ma</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>GY</given-names></name></person-group>. <article-title>Large intervening non-coding RNA HOTAIR is associated with hepatocellular carcinoma progression.</article-title><source>J Int Med Res</source><year>2011</year>;<volume>39</volume>:<fpage>2119</fpage>-<lpage>2128</lpage>.<pub-id pub-id-type="pmid">22289527</pub-id></mixed-citation></ref><ref id="r41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ishibashi</surname><given-names>M</given-names></name><name><surname>Kogo</surname><given-names>R</given-names></name><name><surname>Shibata</surname><given-names>K</given-names></name><name><surname>Sawada</surname><given-names>G</given-names></name><name><surname>Takahashi</surname><given-names>Y</given-names></name><name><surname>Kurashige</surname><given-names>J</given-names></name><etal/></person-group><article-title>Clinical significance of the expression of long non-coding RNA HOTAIR in primary hepatocellular carcinoma.</article-title><source>Oncol Rep</source><year>2013</year>;<volume>29</volume>:<fpage>946</fpage>-<lpage>950</lpage>.<pub-id pub-id-type="pmid">23292722</pub-id></mixed-citation></ref><ref id="r42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Wu</surname><given-names>LM</given-names></name><name><surname>Lai</surname><given-names>MC</given-names></name><name><surname>Xie</surname><given-names>HY</given-names></name><name><surname>Zhang</surname><given-names>F</given-names></name><etal/></person-group><article-title>Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation.</article-title><source>Ann Surg Oncol</source><year>2011</year>;<volume>18</volume>:<fpage>1243</fpage>-<lpage>1250</lpage>.<pub-id pub-id-type="pmid">21327457</pub-id></mixed-citation></ref><ref id="r43"><label>43</label><mixed-citation publication-type="other">Li G, Zhang H, Wan X, Yang X, Zhu C, Wang A, et al. Long noncoding RNA plays a key role in metastasis and prognosis of hepatocellular carcinoma. Biomed Res Int 2014;2014:780521.</mixed-citation></ref><ref id="r44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ding</surname><given-names>C</given-names></name><name><surname>Cheng</surname><given-names>S</given-names></name><name><surname>Yang</surname><given-names>Z</given-names></name><name><surname>Lv</surname><given-names>Z</given-names></name><name><surname>Xiao</surname><given-names>H</given-names></name><name><surname>Du</surname><given-names>C</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR promotes cell migration and invasion via down-regulation of RNA binding motif protein 38 in hepatocellular carcinoma cells.</article-title><source>Int J Mol Sci</source><year>2014</year>;<volume>15</volume>:<fpage>4060</fpage>-<lpage>4076</lpage>.<pub-id pub-id-type="pmid">24663081</pub-id></mixed-citation></ref><ref id="r45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kogo</surname><given-names>R</given-names></name><name><surname>Shimamura</surname><given-names>T</given-names></name><name><surname>Mimori</surname><given-names>K</given-names></name><name><surname>Kawahara</surname><given-names>K</given-names></name><name><surname>Imoto</surname><given-names>S</given-names></name><name><surname>Sudo</surname><given-names>T</given-names></name><etal/></person-group><article-title>Long noncoding RNA HOTAIR regulates polycomb-dependent chromatin modification and is associated with poor prognosis in colorectal cancers.</article-title><source>Cancer Res</source><year>2011</year>;<volume>71</volume>:<fpage>6320</fpage>-<lpage>6326</lpage>.<pub-id pub-id-type="pmid">21862635</pub-id></mixed-citation></ref><ref id="r46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Svoboda</surname><given-names>M</given-names></name><name><surname>Slyskova</surname><given-names>J</given-names></name><name><surname>Schneiderova</surname><given-names>M</given-names></name><name><surname>Makovicky</surname><given-names>P</given-names></name><name><surname>Bielik</surname><given-names>L</given-names></name><name><surname>Levy</surname><given-names>M</given-names></name><etal/></person-group><article-title>HOTAIR long non-coding RNA is a negative prognostic factor not only in primary tumors, but also in the blood of colorectal cancer patients.</article-title><source>Carcinogenesis</source><year>2014</year>;<volume>35</volume>:<fpage>1510</fpage>-<lpage>1515</lpage>.<pub-id pub-id-type="pmid">24583926</pub-id></mixed-citation></ref><ref id="r47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>ZH</given-names></name><name><surname>Wang</surname><given-names>XL</given-names></name><name><surname>Tang</surname><given-names>HM</given-names></name><name><surname>Jiang</surname><given-names>T</given-names></name><name><surname>Chen</surname><given-names>J</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><etal/></person-group><article-title>Long non-coding RNA HOTAIR is a powerful predictor of metastasis and poor prognosis and is associated with epithelial-mesenchymal transition in colon cancer.</article-title><source>Oncol Rep</source><year>2014</year>;<volume>32</volume>:<fpage>395</fpage>-<lpage>402</lpage>.<pub-id pub-id-type="pmid">24840737</pub-id></mixed-citation></ref><ref id="r48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yan</surname><given-names>TH</given-names></name><name><surname>Lu</surname><given-names>SW</given-names></name><name><surname>Huang</surname><given-names>YQ</given-names></name><name><surname>Que</surname><given-names>GB</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><name><surname>Chen</surname><given-names>YP</given-names></name><etal/></person-group><article-title>Upregulation of the long noncoding RNA HOTAIR predicts recurrence in stage Ta/T1 bladder cancer.</article-title><source>Tumour Biol</source><year>2014</year>;<volume>35</volume>:<fpage>10249</fpage>-<lpage>10257</lpage>.<pub-id pub-id-type="pmid">25030736</pub-id></mixed-citation></ref><ref id="r49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zheng</surname><given-names>Y</given-names></name><name><surname>You</surname><given-names>L</given-names></name><name><surname>Kuang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T.</given-names></name></person-group><article-title>Suppressed expression of long non-coding RNA HOTAIR inhibits proliferation and tumourigenicity of renal carcinoma cells.</article-title><source>Tumour Biol</source><year>2014</year>;<volume>35</volume>:<fpage>11887</fpage>-<lpage>11894</lpage>.<pub-id pub-id-type="pmid">25149152</pub-id></mixed-citation></ref><ref id="r50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Qiu</surname><given-names>JJ</given-names></name><name><surname>Lin</surname><given-names>YY</given-names></name><name><surname>Ye</surname><given-names>LC</given-names></name><name><surname>Ding</surname><given-names>JX</given-names></name><name><surname>Feng</surname><given-names>WW</given-names></name><name><surname>Jin</surname><given-names>HY</given-names></name><etal/></person-group><article-title>Overexpression of long non-coding RNA HOTAIR predicts poor patient prognosis and promotes tumor metastasis in epithelial ovarian cancer.</article-title><source>Gynecol Oncol</source><year>2014</year>;<volume>134</volume>:<fpage>121</fpage>-<lpage>128</lpage>.<pub-id pub-id-type="pmid">24662839</pub-id></mixed-citation></ref><ref id="r51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>X</given-names></name><name><surname>Bao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>Z</given-names></name><name><surname>Che</surname><given-names>Q</given-names></name><name><surname>Wang</surname><given-names>H</given-names></name><etal/></person-group><article-title>The long non-coding RNA HOTAIR is upregulated in endometrial carcinoma and correlates with poor prognosis.</article-title><source>Int J Mol Med</source><year>2014</year>;<volume>33</volume>:<fpage>325</fpage>-<lpage>332</lpage>.<pub-id pub-id-type="pmid">24285342</pub-id></mixed-citation></ref><ref id="r52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Ke</surname><given-names>P</given-names></name><name><surname>Guo</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><etal/></person-group><article-title>Lentivirus-mediated RNA interference targeting the long noncoding RNA HOTAIR inhibits proliferation and invasion of endometrial carcinoma cells in vitro and in vivo.</article-title><source>Int J Gynecol Cancer</source><year>2014</year>;<volume>24</volume>:<fpage>635</fpage>-<lpage>642</lpage>.<pub-id pub-id-type="pmid">24758900</pub-id></mixed-citation></ref><ref id="r53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>An</surname><given-names>Y</given-names></name><name><surname>Liang</surname><given-names>Y</given-names></name><name><surname>Xie</surname><given-names>XW</given-names></name></person-group>. <article-title>Role of HOTAIR long noncoding RNA in metastatic progression of lung cancer.</article-title><source>Eur Rev Med Pharmacol Sci</source><year>2014</year>;<volume>18</volume>:<fpage>1930</fpage>-<lpage>1936</lpage>.<pub-id pub-id-type="pmid">25010625</pub-id></mixed-citation></ref><ref id="r54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakagawa</surname><given-names>T</given-names></name><name><surname>Endo</surname><given-names>H</given-names></name><name><surname>Yokoyama</surname><given-names>M</given-names></name><name><surname>Abe</surname><given-names>J</given-names></name><name><surname>Tamai</surname><given-names>K</given-names></name><name><surname>Tanaka</surname><given-names>N</given-names></name><etal/></person-group><article-title>Large noncoding RNA HOTAIR enhances aggressive biological behavior and is associated with short disease-free survival in human non-small cell lung cancer.</article-title><source>Biochem Biophys Res Commun</source><year>2013</year>;<volume>436</volume>:<fpage>319</fpage>-<lpage>324</lpage>.<pub-id pub-id-type="pmid">23743197</pub-id></mixed-citation></ref><ref id="r55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Liu</surname><given-names>ZL</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>ZX</given-names></name><name><surname>De</surname><given-names>W</given-names></name></person-group>. <article-title>The long non-coding RNA HOTAIR indicates a poor prognosis and promotes metastasis in non-small cell lung cancer.</article-title><source>BMC Cancer</source><year>2013</year>;<volume>13</volume>:<fpage>464</fpage>.<pub-id pub-id-type="pmid">24103700</pub-id></mixed-citation></ref><ref id="r56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ono</surname><given-names>H</given-names></name><name><surname>Motoi</surname><given-names>N</given-names></name><name><surname>Nagano</surname><given-names>H</given-names></name><name><surname>Miyauchi</surname><given-names>E</given-names></name><name><surname>Ushijima</surname><given-names>M</given-names></name><name><surname>Matsuura</surname><given-names>M</given-names></name><etal/></person-group><article-title>Long noncoding RNA HOTAIR is relevant to cellular proliferation, invasiveness, and clinical relapse in small-cell lung cancer.</article-title><source>Cancer Med</source><year>2014</year>;<volume>3</volume>:<fpage>632</fpage>-<lpage>642</lpage>.<pub-id pub-id-type="pmid">24591352</pub-id></mixed-citation></ref><ref id="r57"><label>57</label><mixed-citation publication-type="other">Tang L, Zhang W, Su B, Yu B. Long noncoding RNA HOTAIR is associated with motility, invasion, and metastatic potential of metastatic melanoma. Biomed Res Int 2013;2013:251098.</mixed-citation></ref><ref id="r58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>JX</given-names></name><name><surname>Han</surname><given-names>L</given-names></name><name><surname>Bao</surname><given-names>ZS</given-names></name><name><surname>Wang</surname><given-names>YY</given-names></name><name><surname>Chen</surname><given-names>LY</given-names></name><name><surname>Yan</surname><given-names>W</given-names></name><etal/></person-group><article-title>HOTAIR, a cell cycle-associated long noncoding RNA and a strong predictor of survival, is preferentially expressed in classical and mesenchymal glioma.</article-title><source>Neuro Oncol</source><year>2013</year>;<volume>15</volume>:<fpage>1595</fpage>-<lpage>1603</lpage>.<pub-id pub-id-type="pmid">24203894</pub-id></mixed-citation></ref><ref id="r59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>K</given-names></name><name><surname>Jutooru</surname><given-names>I</given-names></name><name><surname>Chadalapaka</surname><given-names>G</given-names></name><name><surname>Johnson</surname><given-names>G</given-names></name><name><surname>Frank</surname><given-names>J</given-names></name><name><surname>Burghardt</surname><given-names>R</given-names></name><etal/></person-group><article-title>HOTAIR is a negative prognostic factor and exhibits pro-oncogenic activity in pancreatic cancer.</article-title><source>Oncogene</source><year>2013</year>;<volume>32</volume>:<fpage>1616</fpage>-<lpage>1625</lpage>.<pub-id pub-id-type="pmid">22614017</pub-id></mixed-citation></ref><ref id="r60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>K</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>M</given-names></name><name><surname>Wu</surname><given-names>W</given-names></name><etal/></person-group><article-title>The long noncoding RNA HOTAIR contributes to cisplatin resistance of human lung adenocarcinoma cells via downregualtion of p21(WAF1/CIP1) expression.</article-title><source>PLoS One</source><year>2013</year>;<volume>8</volume>:<fpage>e77293</fpage>.<pub-id pub-id-type="pmid">24155936</pub-id></mixed-citation></ref><ref id="r61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>X</given-names></name><name><surname>Zhou</surname><given-names>L</given-names></name><name><surname>Fu</surname><given-names>G</given-names></name><name><surname>Sun</surname><given-names>F</given-names></name><name><surname>Shi</surname><given-names>J</given-names></name><name><surname>Wei</surname><given-names>J</given-names></name><etal/></person-group><article-title>The identification of an ESCC susceptibility SNP rs920778 that regulates the expression of lncRNA HOTAIR via a novel intronic enhancer.</article-title><source>Carcinogenesis</source><year>2014</year>;<volume>35</volume>:<fpage>2062</fpage>-<lpage>2067</lpage>.<pub-id pub-id-type="pmid">24788237</pub-id></mixed-citation></ref><ref id="r62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Zhu</surname><given-names>G</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Deng</surname><given-names>Q</given-names></name><name><surname>Katsaros</surname><given-names>D</given-names></name><name><surname>Mayne</surname><given-names>ST</given-names></name><etal/></person-group><article-title>Association of large noncoding RNA HOTAIR expression and its downstream intergenic CpG island methylation with survival in breast cancer.</article-title><source>Breast Cancer Res Treat</source><year>2012</year>;<volume>136</volume>:<fpage>875</fpage>-<lpage>883</lpage>.<pub-id pub-id-type="pmid">23124417</pub-id></mixed-citation></ref><ref id="r63"><label>63</label><mixed-citation publication-type="other">Yang G, Zhang S, Gao F, Liu Z, Lu M, Peng S, et al. Osteopontin enhances the expression of HOTAIR in cancer cells via IRF1. Biochim Biophys Acta 2014;1839:837-848.</mixed-citation></ref><ref id="r64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhan</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>I</given-names></name><name><surname>Ansari</surname><given-names>KI</given-names></name><name><surname>Kasiri</surname><given-names>S</given-names></name><name><surname>Bashyal</surname><given-names>A</given-names></name><name><surname>Mandal</surname><given-names>SS</given-names></name></person-group>. <article-title>Antisense transcript long noncoding RNA (lncRNA) HOTAIR is transcriptionally induced by estradiol.</article-title><source>J Mol Biol</source><year>2013</year>;<volume>425</volume>:<fpage>3707</fpage>-<lpage>3722</lpage>.<pub-id pub-id-type="pmid">23375982</pub-id></mixed-citation></ref><ref id="r65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhuang</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Nguyen</surname><given-names>HT</given-names></name><name><surname>Zhuo</surname><given-names>Y</given-names></name><name><surname>Cui</surname><given-names>X</given-names></name><name><surname>Fewell</surname><given-names>C</given-names></name><etal/></person-group><article-title>Induction of long intergenic non-coding RNA HOTAIR in lung cancer cells by type I collagen.</article-title><source>J Hematol Oncol</source><year>2013</year>;<volume>6</volume>:<fpage>35</fpage>.<pub-id pub-id-type="pmid">23668363</pub-id></mixed-citation></ref><ref id="r66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bhan</surname><given-names>A</given-names></name><name><surname>Hussain</surname><given-names>I</given-names></name><name><surname>Ansari</surname><given-names>KI</given-names></name><name><surname>Bobzean</surname><given-names>SA</given-names></name><name><surname>Perrotti</surname><given-names>LI</given-names></name><name><surname>Mandal</surname><given-names>SS</given-names></name></person-group>. <article-title>Bisphenol-A and diethylstilbestrol exposure induces the expression of breast cancer associated long noncoding RNA HOTAIR in vitro and in vivo.</article-title><source>J Steroid Biochem Mol Biol</source><year>2014</year>;<volume>141</volume>:<fpage>160</fpage>-<lpage>170</lpage>.<pub-id pub-id-type="pmid">24533973</pub-id></mixed-citation></ref><ref id="r67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>ZY</given-names></name><name><surname>Yu</surname><given-names>QM</given-names></name><name><surname>Du</surname><given-names>YA</given-names></name><name><surname>Yang</surname><given-names>LT</given-names></name><name><surname>Dong</surname><given-names>RZ</given-names></name><name><surname>Huang</surname><given-names>L</given-names></name><etal/></person-group><article-title>Knockdown of long non-coding RNA HOTAIR suppresses tumor invasion and reverses epithelial-mesenchymal transition in gastric cancer.</article-title><source>Int J Biol Sci</source><year>2013</year>;<volume>9</volume>:<fpage>587</fpage>-<lpage>597</lpage>.<pub-id pub-id-type="pmid">23847441</pub-id></mixed-citation></ref><ref id="r68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>H</given-names></name><name><surname>Cai</surname><given-names>K</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Cheng</surname><given-names>K</given-names></name><name><surname>Shi</surname><given-names>F</given-names></name><etal/></person-group><article-title>MiR-7, inhibited indirectly by lincRNA HOTAIR, directly inhibits SETDB1 and reverses the EMT of breast cancer stem cells by downregulating the STAT3 pathway.</article-title><source>Stem Cells</source><year>2014</year>;<volume>32</volume>:<fpage>2858</fpage>-<lpage>2868</lpage>.<pub-id pub-id-type="pmid">25070049</pub-id></mixed-citation></ref><ref id="r69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>XH</given-names></name><name><surname>Sun</surname><given-names>M</given-names></name><name><surname>Nie</surname><given-names>FQ</given-names></name><name><surname>Ge</surname><given-names>YB</given-names></name><name><surname>Zhang</surname><given-names>EB</given-names></name><name><surname>Yin</surname><given-names>DD</given-names></name><etal/></person-group><article-title>Lnc RNA HOTAIR functions as a competing endogenous RNA to regulate HER2 expression by sponging miR-331-3p in gastric cancer.</article-title><source>Mol Cancer</source><year>2014</year>;<volume>13</volume>:<fpage>92</fpage>.<pub-id pub-id-type="pmid">24775712</pub-id></mixed-citation></ref></ref-list></back></article>